ArticleJournal of ovarian research2026
Astaxanthin attenuates CTX-induced premature ovarian failure by alleviating ovarian apoptosis and autophagy in vivo.
Article in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundCyclophosphamide (CTX) is a commonly used chemotherapeutic agent for breast cancer that frequently causes premature ovarian failure (POF), a clinical syndrome characterized by menstrual irregularities in women under the age of 40 years, accompanied by elevated serum follicle-stimulating hormone (FSH) and decreased estrogen levels. Astaxanthin (AS), a natural antioxidant, has been shown to exert various biological effects, including anti-aging and anti-inflammatory effects. However, further investigation into its anti-ovarian aging mechanism is warranted.
methodsTwo-month-old female mice and CTX-induced POF model mice were used. Hematoxylin and eosin staining, immunohistochemical staining, TUNEL assays, Western blotting, and qPCR analyses were employed to evaluate ovarian function and related phenotypes after astaxanthin treatment. Subsequently, network pharmacology analysis was used to elucidated potential targets.
resultsAstaxanthin intervention significantly ameliorated estrous cycle disorder in POF mice and restored serum levels of anti-Müllerian hormone (AMH) and estradiol (E
conclusionThis study elucidates the mechanism by which astaxanthin improves ovarian function through the CYP19A1, providing potential molecular targets and therapeutic strategies for the clinical treatment of POF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.